News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
OncoGenex (OGXI) To Report First Quarter 2016 Financial Results On May 12, 2016 4/29/2016
Can-Fite BioPharma (CFBI) To Present At Joseph Gunnar & Co.'s Pioneers 2016 Conference In New York City On May 5, 2016 4/29/2016
Eleven Biotherapeutics (EBIO) To Present Data At The Association for Research in Vision & Ophthalmology 2016 Annual Meeting 4/29/2016
Takeda (TKPYY) Release: Phase 3 Trial Results For First Oral Proteasome Inhibitor NINLARO (Ixazomib) Published In The New England Journal Of Medicine 4/28/2016
Celgene (CELG) Reports First Quarter 2016 Operating And Financial Results 4/28/2016
Novartis AG (NVS) Granted Three Breakthrough Badges for Ilaris 4/27/2016
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S. 4/27/2016
Cytori Therapeutics (CYTX) Announces Timing For Full Enrollment In U.S. Phase III Scleroderma Trial 4/27/2016
Servier Release: Patients With Advanced Metastatic Colorectal Cancer In Europe Now Have A New Treatment Option As LONSURF(Trifluridine/Tipiracil) Receives EU Approval 4/27/2016
Sunovion Pharmaceuticals Inc. Announces Positive Results From Two Phase III Clinical Studies Evaluating SUN-101/Eflow (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 4/27/2016
From 20 to 84 Employees in Just Four Years, Booming Blueprint Medicines (BPMC) Maps Out a Plan 4/26/2016
DalCor Randomizes First Patient In The DalGenE Phase 3 Cardiovascular Outcomes Trial 4/26/2016
Celsion (CLSN) Announces Enrollment Of First Patient In The OPTIMA Study In China 4/26/2016
Pfizer (PFE) Release: Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled 4/26/2016
Actinium Pharmaceuticals, Inc. (ATNM.OB) To Host Webinar To Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study For Iomab-B 4/26/2016
JAMA Publishes Phase III Data From Allergic Asthma Trial With ALK-Abello A/S's House Dust Mite SLIT-Tablet, ACARIZAX 4/26/2016
SIGA (SIGA) Announces Enrollment Of First Patients In The Final Cohort Of Phase III Study Of Tecovirimat 4/26/2016
Bristol-Myers Squibb (BMY)’s Opdivo Tagged a Breakthrough by the FDA for Head and Neck Cancer 4/25/2016
No Suicide Risk Linked to Pfizer (PFE)'s Chantix 4/25/2016
PHARNEXT Announces The Opening Of The First U.S. Study Site For Its PLEO-CMT International Pivotal Phase 3 Trial In Charcot-Marie-Tooth Disease Type 1A 4/25/2016
Merck KGaA (MKGAF.PK) Release: Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone 4/25/2016
Biogen (BIIB) R&D Spending Dropped 19% from Last Quarter 4/22/2016
QLT (QLTI) Completes Enrollment In Its Natural History Study 4/22/2016
Celator Pharma (CPXX) To Present Phase 3 Data At 2016 ASCO Annual Meeting 4/21/2016
MedDay Reports Full Data From Pivotal Phase IIb/III MS-SPI / MS-ON Studies With MD1003 In Multiple Sclerosis At AAN 4/21/2016
Novartis AG (NVS)'s Afinitor Significantly Reduces Seizures in TSC Patients in Late Stage Study 4/21/2016
FDA Removes Clinical Hold on Cara Therapeutics (CARA)'s Phase III Postoperative Pain Study 4/20/2016
Basilea (BSLN.SW) Wins $100 Million Contract to Fund Phase III Ceftobiprole Program 4/20/2016
Mitsubishi Tanabe Presents Edaravone Clinical Trial Data In ALS At 2016 American Academy of Neurology Annual Meeting 4/20/2016
Amgen (AMGN) Release: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia 4/20/2016
CytRx (CYTR) To Present Updated Aldoxorubicin Clinical Trial Data At The ASCO Annual Meeting In June 2016 4/20/2016
Exelixis (EXEL)-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting 4/20/2016
Genmab A/S (GEN.CO) Announces Daratumumab Data To Be Presented At 2016 ASCO Annual Meeting 4/20/2016
AbbVie (ABBV) Release: Data Presented At AAN Highlight Impact Of ZINBRYTA (Daclizumab HYP) On Cognitive Outcomes And The Reversibility Of Its Targeted Mechanism Of Action 4/20/2016
Eli Lilly (LLY) Abandons Development of Transition Therapeutics (TTH.TO)' Diabetes Candidate TT401 4/19/2016
Marathon Pharma Presents Analyses At American Academy of Neurology Of A Phase III Clinical Study Of Deflazacort In Patients With Duchenne Muscular Dystrophy (DMD) 4/19/2016
Northwestern Medicine Release: New Research Finds Islet Transplantation Effective To Treat Type 1 Diabetes Complicated By Severe Hypoglycemia 4/19/2016
Tris Pharma, Inc. Announces The Launch Of DYANAVEL XR (Amphetamine) Extended-Release Oral Suspension, CII For The Treatment Of Children With ADHD 4/19/2016
XBiotech USA (XBIT) To Present Pivotal Phase III Data On Xilonix At European Society Of Medical Oncology’s World Congress On Gastrointestinal Cancer 4/19/2016
Bristol-Myers Squibb (BMY) Release: First Presentation Of Overall Survival Data For Opdivo (Nivolumab) Shows Significant Survival Benefit At One-Year Versus Investigator’s Choice In Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck 4/19/2016
Celator Pharma (CPXX) Reports On Previously Suspended Investigator-Initiated Clinical Study 4/19/2016
Dynavax (DVAX) Presents Pivotal Phase 3 Data Showing HEPLISAV-B Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B 4/19/2016
Pfizer (PFE) Announces Positive Top-Line Results For Phase III PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib) 4/19/2016
Acucela Announces End Of Treatment Period In Phase 2b/3 Clinical Trial Of Emixustat Hydrochloride 4/19/2016
Celsion (CLSN) Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin And Doxil 4/19/2016
Merck & Co. (MRK)'s Hep C Drug ZEPATIER Shows Cure Rates as High as 96% in Phase III Studies 4/18/2016
RedHill Biopharma (RDHL) Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection 4/18/2016
Celator Pharma (CPXX) Announces New Data For VYXEOS In FLT3-ITD Mutated AML Cells Derived From Patients With Newly Diagnosed AML To Be Presented At The AACR Annual Meeting 4/18/2016
AVANIR (AVNR) To Present Data On NUEDEXTA And ONZETRA Xsail At American Academy of Neurology 2016 Annual Meeting 4/18/2016
Morphotek Announces Publication Of Phase 3 Results From Morab-003-004 Trial In Platinum-Sensitive Ovarian Cancer Patients 4/18/2016
Biogen (BIIB) Release: TECFIDERA Data Confirm Strong And Sustained Efficacy In Newly Diagnosed MS Patients And Real-World Effectiveness 4/18/2016
Teva (TEVA) Presents New Data For SD-809 In Huntington Disease At 68th American Academy of Neurology Annual Meeting In Vancouver, B.C. 4/18/2016
Merck & Co. (MRK) Announces Results From Phase 3 Studies Of ZEPATIER (Elbasvir And Grazoprevir) In Chronic Hepatitis C Patient Populations At The International Liver Congress 4/18/2016
Seattle Genetics (SGEN) Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances At AACR Annual Meeting 4/18/2016
Gilead (GILD) Announces Multiple Scientific Presentations Demonstrating Broad Utility Of Sofosbuvir-Based Hepatitis C Therapies 4/18/2016
Titan Pharma (TTP) Announces Presentation Of Probuphine Phase III Data At American Society Of Addiction Medicine Annual Conference 4/18/2016
AbbVie (ABBV) Announces Real-World Data With VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) And EXVIERA (Dasabuvir Tablets) From Large German Hepatitis C-Registry 4/15/2016
Enanta Pharmaceuticals, Inc. Announces High SVR Rates With AbbVie (ABBV)’s VIEKIRAX + EXVIERA Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients 4/15/2016
Braeburn Pharma Release: Probuphine Phase III Data Presented At American Society Of Addiction Medicine (ASAM) Annual Meeting 4/15/2016
Repros Therapeutics (RPRX) to Ditch Efforts to Seek Approval of Testosterone Drug in the U.S. if Key Study Fails 4/15/2016
Gilead (GILD)'s Hep B Candidate Delivers in Two Late-Stage Studies 4/15/2016
ContraVir Invited To Present CMX157 Data At CHI's Eleventh Annual Drug Discovery Chemistry Conference 4/14/2016
Enanta Pharmaceuticals, Inc. Announces High SVR Rates With AbbVie (ABBV)’s Viekirax + Exviera Regardless Of The Presence Of Resistance-Associated Variants Prior To Treatment In Genotype 1 Chronic Hepatitis C Patients 4/14/2016
AbbVie (ABBV) Shows Off Positive Data on Combo HCV Therapy 4/14/2016
Merck & Co. (MRK)’s ZEPATIER (Elbasvir And Grazoprevir) Showed Superiority On Efficacy And Safety Endpoints Compared To Sofosbuvir Plus Peginterferon And Ribavirin Treatment Regimen In Phase 3 Trial 4/14/2016
Booming Seres Therapeutics Looks to Move Lead Product into Phase III, Expand in Cambridge 4/14/2016
Tocagen Inc. To Present Data From Clinical Trials And Preclinical Programs At Four Scientific Conferences 4/13/2016
Actinium Pharmaceuticals, Inc. (ATNM.OB) Announces Selection Of Zevacor Pharma, Inc. For Clinical Production And Supply Of Iomab-B For Pivotal Phase 3 SIERRA Trial 4/13/2016
Tokai Pharmaceuticals (TKAI) Announces Presentations On Galeterone At The AACR Annual Meeting 2016 4/13/2016
Genentech (RHHBY) To Present New Data At American Academy of Neurology Showing Superior Efficacy Of Investigational Medicine Ocrelizumab Versus Comparators On Disease Activity And Progression In Two Forms Of Multiple Sclerosis 4/13/2016
107th Annual Meeting Of AACR: Bayer (BAY) To Present New Data On Advancing Oncology Portfolio 4/13/2016
Celsion (CLSN) Announces Upcoming Presentation At AACR 2016 Highlighting Potential Of GEN-1 IL-12 Immunotherapy In Ovarian Cancer 4/12/2016
Ariad (ARIA) Announces Initiation Of Randomized, First-Line Phase 3 Trial Of Brigatinib In Treatment Of Alk-Positive Non-Small Cell Lung Cancer 4/11/2016
The Medicines Company (MDCO) Release: FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE (meropenem-vaborbactam) 4/11/2016
Medivir (MVRBF): New Data For Simeprevir Will Be Presented At Easl's International Liver Congress 2016 4/11/2016
Addex Therapeutics (ADXN.SW) Reports Positive Results Of An mGlu5 Receptor Occupancy Study With Dipraglurant In Healthy Volunteers 4/11/2016
AstraZeneca PLC (AZN), Eli Lilly (LLY) Alzheimer's Drug Enters Final Testing Stage, Astra Earns $100 Million 4/8/2016
DURECT (DRRX) Falls Premarket After the FDA Asks for PERSIST Trial Amendments 4/8/2016
CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI (enzalutamide) 4/7/2016
Acorda (ACOR) Release: Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy of Neurology Annual Meeting 4/7/2016
FDA Slaps Clinical Hold on Ionis Pharma (IONS) Study While GlaxoSmithKline (GSK) Finalizes Protocol 4/7/2016
3 Biotechs Getting Another Shot After Failed Trials 4/7/2016
Akcea Therapeutics To Present At 15th Annual Needham Healthcare Conference 4/6/2016
Merck & Co. (MRK) To Present New Data For KEYTRUDA (pembrolizumab) At The AACR 2016 Annual Meeting 4/6/2016
Sunovion Pharmaceuticals Inc. To Present Data Analyses Supporting Use Of Aptiom (eslicarbazepine acetate) At The 68th American American Academy of Neurology Annual Meeting 4/6/2016
Pfizer (PFE) Touts Positive Data From Late-Stage Psoriatic Arthritis Drug Trial 4/5/2016
Data Behind Eli Lilly (LLY)'s Decision to Halt Potential Cholesterol Blockbuster Released Last Weekend 4/5/2016
Axovant (AXON) To Present At The Goldman, Sachs & Co. Alzheimer's Symposium 4/5/2016
Celator Pharma (CPXX) To Present At 15th Annual Needham Healthcare Conference 4/5/2016
SELLAS Life Sciences Group Receives A Favorable Opinion For European Orphan Drug Designations For WT1 Cancer Vaccine (galinpepimut-S) For The Treatment Of Acute Myeloid Leukemia And For Malignant Pleural Mesothelioma 4/5/2016
Merck & Co. (MRK) And Pfizer (PFE) Announce First Patient Treated In Phase III Combination Study With Avelumab And INLYTA In Renal Cell Carcinoma 4/5/2016
Highland Therapeutics Announces Positive Pivotal ADHD Trial Results For Its Investigational Drug Candidate Benjorna 4/5/2016
Braeburn Pharma And Camurus Announce Enrollment Goals Reached In Two Pivotal Phase 3 Trials Of CAM2038 For Treatment Of Opioid Dependence 4/5/2016
Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen (AMGN) 4/4/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Tops Teriparatide in Phase III Osteoporosis Study 4/4/2016
Regeneron (REGN)'s Eczema Data Look Great. Don't Believe Me? Ask A Patient 4/4/2016
Cancer Prevention Pharma Completes Target Enrollment In Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/Sulindac In Patients With Familial Adenomatous Polyposis 4/4/2016
Intec Pharma Ltd. Enrolls First Patient In Pivotal Phase III Clinical Trial Of AP-CDLD For Advanced Parkinson's Disease Patients 4/4/2016
Citius Pharma Completes Acquisition Of Leonard-Meron Biosciences 4/4/2016
CytRx (CYTR) Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis 4/4/2016
Zafgen (ZFGN) Presents New Data From The Phase III Bestpws Study Evaluating Beloranib In Prader-Willi Syndrome At ENDO 2016 4/4/2016
Amgen (AMGN) Release: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association" 4/4/2016
Flexion (FLXN) Announces Presentation Of Results From Pivotal Phase IIb And Phase III Clinical Trials For Zilretta At Osteoarthritis Research Society International (OARSI) 2016 World Congress 4/4/2016
Novo Nordisk A/S (NVO) Release: Saxenda (liraglutide [rDNA origin] Injection) Demonstrated Significant Improvements In Cardiometabolic Risk Factors Over Three Years Compared With Placebo 4/4/2016
Mast Therapeutics (MSTX) Release: Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College of Cardiology 65th Annual Scientific Sessions & Expo 4/4/2016
Boehringer Ingelheim Pharmaceuticals, Inc. Release: : Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) In Emergency Situations 4/4/2016
Novo Nordisk A/S (NVO) Release: Semaglutide Demonstrated Superior Improvements In Glycemic Control Vs Placebo In Adults With Type 2 Diabetes 4/4/2016
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On April 4-6, 2016 In Stockholm, Sweden 4/4/2016
Shire (SHPG) Announces Positive Results Of SHP465 Safety And Efficacy Study In Children And Adolescents With ADHD 4/4/2016
Chugai Pharma Europe Announces Positive Phase III Results Of Aplidin 4/4/2016
TherapeuticsMD, Inc.  (TXMD) Presents Detailed Results From Phase 3 Rejoice Trial In Postmenopausal Women With Vulvar And Vaginal Atrophy (VVA) At ENDO 2016 4/4/2016
Onxeo Announces Positive DSMB Recommendation To Continue Livatag Relive Study In HCC 4/4/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry 4/4/2016
Can-Fite BioPharma (CFBI) Reports 2015 Financial Results & Provides Clinical Pipeline Update 4/1/2016
Pfizer (PFE)'s Bococizumab Met Primary Endpoints in Phase III Trial 4/1/2016
Array BioPharma (ARRY) to Abandon Testing of Ovarian Cancer Drug 4/1/2016
Rigel (RIGL) Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP 4/1/2016
Asterias Biotherapeutics Announces Record Date For Distribution Of Warrants To Holders Of Asterias Series A Common Stock 4/1/2016
Taiho Pharma's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Phase III TERRA Study In Asian Patients With Refractory Metastatic Colorectal Cancer 4/1/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In March For Its Phase III Head And Neck Cancer Trial 4/1/2016
Supernus Pharmaceuticals (SUPN) Selects DSG, Inc. For EDC And IWRS In Phase III Clinical Studies On Impulsive Aggression In Pediatric Patients Treated For Attention Deficit/Hyperactivity Disorder (ADHD) 4/1/2016
Eli Lilly (LLY), Incyte (INCY) Tout Late-Stage Study Data of Rheumatoid Arthritis Drug Baricitinib 3/31/2016
Celator Pharma (CPXX) Announces New Data For VYXEOS In FLT3-ITD Mutated AML Cells Derived From Patients With Newly Diagnosed AML To Be Presented At The AACR Annual Meeting 3/31/2016
Lexicon Pharma (LXRX) Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome 3/31/2016
Ionis Pharma (IONS) Advances Nusinersen In The Ongoing SHINE Study In Patients With SMA 3/31/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Announces 2015 Financial Results 3/31/2016
Iroko Pharmaceuticals To Present Phase 3 VIVLODEX Efficacy And Safety Data At World Congress Of Osteoarthritis 3/31/2016
Specialised Therapeutics Asia Release: Novel Multiple Myeloma Drug Aplidin Shows Positive Results In Pivotal Phase 3 Study 3/31/2016
Opko Health (OPK) Presents Additional Data On RAYALDEE To Treat Secondary Hyperparathyroidism In Chronic Kidney Disease 3/31/2016
Akcea Therapeutics Supports World Lipodystrophy Day 3/31/2016
Celsion (CLSN) Reports Year End 2015 Financial Results And Provides Business Update 3/30/2016
Auris Medical AG (EARS) Completes Enrollment Of TACTT2 Phase 3 Trial Of AM-101 In Acute Inner Ear Tinnitus 3/30/2016
Merck & Co. (MRK) To Present New Findings From Chronic Hepatitis C Clinical Development Programs At The International Liver Congress 2016 3/30/2016
AbbVie (ABBV) To Present Data On VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) And EXVIERA (dasabuvir tablets) And Investigational, Pan-Genotypic Regimen At The International Liver Congress 2016 3/30/2016
Highland Therapeutics Announces Trade Name Benjorna™ For Its Next-Generation ADHD Medicine 3/30/2016
Janssen Research & Development Release: First Phase 3 Trial Of Daratumumab In Combination With Standard Therapy In Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint In Planned Interim Analysis 3/30/2016
Keryx (KERX)'s Anemia Drug Ferric Citrate Succeeds in Phase III Study of Kidney Patients 3/29/2016
SillaJen Enrolls First U.S. Patient In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer 3/29/2016
Ampio Pharmaceuticals, Inc. (AMPE) Completes Enrollment In Pivotal Clinical Trial Of AMPION 3/29/2016
Zafgen (ZFGN) To Present Data From Bestpws Study Of Beloranib In Prader-Willi Syndrome At ENDO 2016 3/29/2016
ImmunoCellular Therapeutics, Ltd (IMUC) To Report 2015 Financial Results On March 30, 2016 3/29/2016
Portola (PTLA) Craters as Long-Acting Blood Thinner Betrixaban Missed Primary Goal in Phase III Study 3/25/2016
Astellas (ALPMY) Release: Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer 3/24/2016
Mezzion (140410.KQ) Receives Special Protocol Assessment (SPA) Agreement From FDA For Udenafil Phase 3 Studies In Adolescents With Single Ventricle Congenital Heart Disease With Fontan Physiology 3/24/2016
Medivation (MDVN) Release: Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer 3/24/2016
Daiichi Sankyo To Present Findings From New Subgroup Analyses Of Once-Daily SAVAYSA (edoxaban) In NVAF And VTE At American College of Cardiology's 65th Annual Scientific Session 3/24/2016
Cytori Therapeutics (CYTX) Update On Its U.S. Phase III Scleroderma Trial 3/24/2016
Soligenix (SNGX) Announces Recent Accomplishments And Year-End 2015 Financial Results 3/24/2016
Celator Pharma (CPXX) Announces Proposed Public Offering Of Common Stock 3/23/2016
Regeneron (REGN) And Sanofi (SNY) Announce Positive Topline Results From Phase 3 Praluent (alirocumab) Study In Patients Undergoing LDL Apheresis Therapy 3/23/2016
Dipexium Pharmaceuticals (DPRX) Reports 2015 Financial Results 3/23/2016
Celsion (CLSN) To Hold Year-End 2015 Financial Results Conference Call On Wednesday, March 30, 2016 3/23/2016
Advanced Accelerator Applications Provides Lutathera Update 3/23/2016
Inotek Pharmaceuticals Corporation (ITEK) Reports Fiscal Year 2015 Financial Results And Operational Highlights 3/23/2016
Amgen (AMGN) to Present 19 Abstracts at American College of Cardiology 3/22/2016
Janssen Research & Development Announces The Initiation Of Two Studies Evaluating Daratumumab (DARZALEX) And Atezolizumab In Multiple Myeloma And Solid Tumor 3/22/2016
Mologen AG (MOLGF.PK): All Key Milestones Achieved In 2015 3/22/2016
Four Biopharma Company Stocks Take Bounces on Good News 3/22/2016
Investors are Irked as BioMarin (BMRN)'s Pegvaliase Shows Mixed Results in Pivotal Study 3/21/2016
Ritter Pharmaceuticals, Inc. Doses First Patient In Phase 2b/3 Trial Of RP-G28 In Lactose Intolerance 3/21/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Shines in Phase III Osteoporosis Trial 3/21/2016
TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July 3/21/2016
Acacia Pharma Initiates Second Pivotal Phase 3 Treatment Study With Baremsis (APD421) In Post-Operative Nausea & Vomiting (PONV) 3/21/2016
Juniper Pharma (JNP) Affirms Development Pathway For Oxybutynin Intra-Vaginal Ring For Overactive Bladder In Women 3/21/2016
Tokai Pharmaceuticals (TKAI) Strengthens Development Team Through The Addition Of Kelly Lindert, M.D., As Executive Vice President And Head Of Development 3/21/2016
Hutchison China MediTech (Chi-Med) Initiates Sulfatinib Phase III Registration Study In Pancreatic Neuroendocrine Tumor Patients 3/21/2016
Pfizer (PFE)'s Oral Tofacitinib Meets Primary and Key Secondary Endpoints in Two Late-Stage Trials 3/18/2016
After Mixed Clinical Trial Results, Bay Area’s Carbylan Engages Wedbush PacGrow to Evaluate Options 3/18/2016
Eli Lilly (LLY) Dropped After Primary Goal of Alzheimer's Study Was Changed 3/18/2016
ARCA biopharma Announces Fiscal Year 2015 Financial Results And Provides Business Update 3/18/2016
TiGenix Presents 24 Week Results Of Its Cx601 Phase III Trial At ECCO 2016 3/18/2016
Janssen Research & Development Release: STELARA Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy 3/18/2016
Fabre Kramer Pharmaceuticals, Inc. Release: FDA Rules Favorably On Efficacy Of Travivo (Gepirone ER) For Treatment Of Major Depressive Disorder 3/18/2016
Can-Fite BioPharma (CFBI) Submits Phase III Protocol Design And Registration Plan To European Medicines Agency For CF101 In The Treatment Of Rheumatoid Arthritis 3/17/2016
Celsion (CLSN) Announces Presentation Of Preclinical Data For GEN-1 IL-12 Immunotherapy In Combination With Avastin And Doxil At The AACR Annual Meeting 2016 3/17/2016
Tocagen Inc. To Present At Three Oncology Conferences 3/17/2016
Bristol-Myers Squibb (BMY) To Present New Overall Survival Data For Opdivo (nivolumab) As Monotherapy And In Combination With Yervo (ipilimumab) At The AACR 2016 Annual Meeting 3/17/2016
ERYtech Pharma To Present Two Posters At AACR 3/17/2016
AMAG (AMAG) Announces First Patient Enrolled In Head-To-Head Phase III Clinical Trial Evaluating Feraheme® In Adults With Iron Deficiency Anemia 3/16/2016
Provectus Amends Protocol For Phase 3 Study Of PV-10 In Treatment Of Locally Advanced Cutaneous Melanoma 3/16/2016
Celator Pharma (CPXX) Stock Jumps 400% Premarket as AML Drug Wows in Phase III Study 3/16/2016
GW Pharma (GWPH) Shares Double as Cannabis Drug Meets Goals in Phase III Study 3/15/2016
Heart Metabolics Limited Announces Multiple Senior Appointments To Management Team 3/15/2016
Achaogen (AKAO) Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update 3/15/2016
AVEO Oncology (AVEO) Reports Full Year 2015 Financial Results And Provides Business Update 3/15/2016
Janssen-Cilag International NV (JNJ) Release: Greater Survival Benefit Shown In Men With Early And Less Aggressive Metastatic Castration-Resistant Prostate Cancer Treated With ZYTIGA Plus Prednisone 3/14/2016
Ritter Pharmaceuticals, Inc. Initiates Phase 2B/3 Clinical Trial Of RP-G28 In Lactose Intolerance 3/14/2016
Embattled Bay Area XOMA  (XOMA) Terminates Gevokizumab Trials 3/14/2016
AcelRx (ACRX) Advances ARX-04 Into Extension Phase Of Open-Label Phase 3 Emergency Room Study 3/14/2016
Quark Pharmaceuticals Inc. Doses First Patients In Two Pivotal Phase III Studies And One Phase II Study Of RNAi-Based Therapeutics For Kidney And Eye Indications 3/14/2016
PTC Therapeutics (PTCT) Announces Presentation Of Results From Phase 3 ACT DMD Clinical Trial Of Translarna (ataluren) In Patients With Duchenne Muscular Dystrophy At 5th International Congress Of Myology 3/14/2016
PTC Therapeutics (PTCT) Provides Update On Health Canada Review Of Translarna (ataluren) For The Treatment Of Duchenne Muscular Dystrophy 3/14/2016
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2015 Financial Results 3/14/2016
BioLife Solutions, Inc. (BLFS.OB) Provides Update On Customer Cell Therapy Clinical Trials And Development Programs 3/14/2016
Accera, Inc. To Present At BIO Asia International Conference 3/14/2016
Regeneron (REGN), Sanofi (SNY)'s RA Drug Beats AbbVie (ABBV)'s Blockbuster Humira in Phase III Study 3/14/2016
Alzheon Wants Another Shot at Alzheimer's, Presents Data for Tweaked Phase III Studies on Once-Rejected Drug Tramiprosate 3/11/2016
RedHill Biopharma (RDHL) Reports Successful Final Results Of Phase III Study With RHB-105 For H. pylori Infection 3/10/2016
OncoGenex (OGXI) Reports Financial Results for Year End 2015 3/10/2016
Hemispherx (HEB) Reviews Ampligen Data With National Institute Of Neurological Disorders 3/10/2016



//-->